… -19 and tested in clinical trials. The aim of this literature review is to investigate the efficacy
and safety of repurposed pharmacological agents for the treatment of COVID-19 at different …

… for repurposing/repositioning in the therapy of the COVID-19 … drugs re-considered for COVID-19
therapy are or have been … amenable of repurposing for the therapy of COVID-19, we can …

… Hence, the search for effective therapeutic agents to tackle COVID-19 is … In recent times,
repurposing of available drugs for the … other health agencies to treat emerging health problems. …

… Total 61 reported antiviral agents from the beginning of antiviral chemotherapy year 1960 to
… to screen and identify the potent antiviral agents specifically for COVID-19 [10,11]. PubChem …

… COVID-19 pandemic, regulatory agency decisions may have to accelerate their decision
process, thus collaboration and communication between national regulatory and HTA agencies …

… repurposing have helped to address the urgent need for antiviral drugs against COVID-19
using representative repurposing … SARS-CoV-2 is indeed the causative agent of COVID-19. …

… Next, we conduct an overview of different repurposed agents that have been considered for
COVID-19 treatment (Table 2). Unfortunately, some of them did not show benefits for patients…

… properties could be repurposed as a dual function … agents or other targeted therapies that
show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent …

… A summary of repurposed agents for COVID-19 … view, the drug repurposing strategy to face
COVID-19 has offered a … trials investigating repurposed agents for the treatment of COVID-19, …

… Another monoclonal antibody or immune modulatory agents in clinical trials in China or
existing for prolonged admittance in the US comprise bevacizumab (anti–vascular endothelial …